Skip to main content
Autobound logo
Incyte10-K: Software implementation

Anticipating regulatory decision and commercial launch of JAKAFI XR in mid-2026.

Read at SEC EDGAR

What happened

Following a previous FDA rejection, the company has successfully completed a new study and resubmitted its application.

Source

SEC EDGARFeb 10, 2026

Annual report (Form 10-K)

Incyte 10-K for FY2025

Filing excerpt

In early 2025, we announced that a bioequivalence study of ruxolitinib XR was completed and the bioequivalence criteria were met.

sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htmRead the full source

Other signals in this filing (11)

Extracted by Autobound

From the Signal API record
Signal
10-K: Software implementation

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 10, 2026

More from Incyte

Company page →

More 10-K signals at other companies

The full record

From the Signal API record

Details

CIK
879169
Accession number
0000879169-26-000010
Timeframe
Current year
Filing year
2026
Why it matters
Implementation partner opportunity
Signal category
Technology

Extraction

Confidence
High
Relevance
90%
Sentiment
Positive
Detected
Feb 17, 2026
signal_type
sec-10k
signal_subtype
softwareImplementation

Use this data

Get every 10-K signal for Incyte and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/0d30edda-2805-4995-ab30-53ba405acc76 returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.

{
  "signal_id": "0d30edda-2805-4995-ab30-53ba405acc76",
  "signal_type": "sec-10k",
  "signal_subtype": "softwareImplementation",
  "detected_at": "2026-02-17T06:34:03.067+00:00",
  "company": {
    "name": "Incyte",
    "domain": "incyte.com"
  },
  "data": {
    "detail": "Following a previous FDA rejection, the company has successfully completed a new study and resubmitted its application. An upcoming launch for a new formulation of a blockbuster drug signals significant budget allocation for sales, marketing, and distribution systems.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "Anticipating regulatory decision and commercial launch of JAKAFI XR in mid-2026.",
    "excerpts": "In early 2025, we announced that a bioequivalence study of ruxolitinib XR was completed and the bioequivalence criteria were met.",
    "relevance": 0.9,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/879169/000087916926000010/incy-20251231.htm",
    "filing_date": "2026-02-10",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "Implementation partner opportunity",
    "signal_category": "technology"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.